NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Health Information Services · USD

Mangoceuticals, Inc. (MGRX) Stock Analysis

Mangoceuticals, Inc. (MGRX) is a Health Information Services stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

MGRX

$0.30

−$0.00 (−1.63%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MGRX with… →

MGRX Key Statistics

As of Oct 21, 2026
Trading
Open
$0.29
Previous Close
$0.30
Day's Range
0.29–0.31
52-Week Range
0.16–2.75
Volume
75.92K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.98
Valuation
Market Cap
$6.56M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
20.81
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.02
Financials (FY)
Revenue (FY)
$456.02K−25.96%
Net Income (FY)
−$20.64M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
22.22M
1-Year Return
−89.23%
Dividend and dates
Avg Volume
12.81M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, MGRX closed at $0.30, −89.23% over 1 year.

Mangoceuticals, Inc. (MGRX) has a market capitalization of $6.56M.

In fiscal 2025, MGRX reported revenue of $456.02K.

MGRX Stock Return by Calendar Year

Mangoceuticals, Inc. (MGRX) return since Mar 2023: what $10,000 became

1 year
$10,000 $1,077
−89.23%
3 years
$10,000 $203
−97.97%
Since Mar 2023
$10,000 $49
−99.51%

If you had invested $10,000 in Mangoceuticals, Inc. (MGRX) at the close on March 21, 2023, the earliest close on record here, it would have been worth $49 at the close on October 21, 2026: −99.51% in total, −77.28% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−60.12%
2025−69.42%
2024−41.76%
2023 (partial year)−93.08%

As of October 21, 2026.

MGRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$456.02K−$20.64M−4,526.8%
2024$615.87K−$8.71M−1,413.6%
2023$731.49K−$9.21M−1,259.4%
2022$8.94K−$2.00M−22,352.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$456.02K$250.39K−$19.15M−$20.64M−4,526.8%
2024$615.87K$379.96K−$8.69M−$8.71M−1,413.6%
2023$731.49K$431.50K−$9.22M−$9.21M−1,259.4%
2022$8.94K$4.85K−$1.99M−$2.00M−22,352.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MGRX Valuation vs Health Information Services Median

Median of 44 stocks
MetricMGRXHealth Information Services medianvs median
P/S ratio20.812.319.0x the median

Medians across 44 Health Information Services stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Mangoceuticals, Inc. (MGRX) at $6.56M. The company sits in the Healthcare sector, in the Health Information Services industry. The company reports 3 employees.

MGRX last closed at $0.30 on October 21, 2026. That is $0.00 (−1.63%) against the previous close. The 52-week range on file runs from $0.16 to $2.75. The latest close sits 82.16% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $456.02K. Against the prior fiscal year total of $615.87K, that is a change of −25.96%. The same year closed with a net loss of $20.64M. Earnings per share on a trailing basis come to −1.02.

Across the 4 fiscal years on file, revenue moves from $8.94K in 2022 to $456.02K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 20.81. On price-to-sales that is 9 times the Health Information Services median of 2.31. 44 Health Information Services companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.98. Annualized volatility over the trailing 3 years is 168.91%. Over the trailing twelve months the total return is −89.23%. Measured over 3 years, that is −72.71% a year compounded.

Growth & Income

The record shows no dividend for MGRX.

2026 is still running; the total return is −60.12% year to date. The strongest complete calendar year on file is 2024 at −41.76%; the weakest is 2025 at −69.42%.

Peer Comparison

Mangoceuticals, Inc. (MGRX) operates in the Health Information Services industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Mangoceuticals, Inc. MGRX $6.56M —
Veeva Systems Inc. VEEV $51.90B 52.6
BrightSpring Health Services, Inc. BTSG $12.40B 55.4
Tempus AI, Inc. TEM $12.23B —

The Health Information Services industry average P/E ratio is 46.5x. Mangoceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Health Information Services Stocks

VEEV

Veeva Systems Inc.

$51.90B

 BTSG

BrightSpring Health Services, Inc.

$12.40B

 TEM

Tempus AI, Inc.

$12.23B

 HNGE

Hinge Health, Inc.

$9.04B

 HQY

HealthEquity, Inc.

$8.10B

 DOCS

Doximity, Inc.

$5.99B
View all Health Information Services stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Mangoceuticals, Inc.

Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. In addition, the company markets and sells its products online through its website www.MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.

Visit website →